A股異動丨之江生物(688317.SH)漲超8% 已開發能鑑別變異株的產品
格隆匯8月3日丨之江生物(688317.SH)持續反彈,5日累計漲幅達25%。現漲超8%,報72.6元,總市值超140億元。之江生物在接受機構調研時表示,去年因為新冠疫情帶動了整體的營收,除了新冠核酸檢測試劑外還有儀器設備和提取試劑的銷量的增加。今年國外疫情比較嚴峻,國內也有散發出現,檢測量還是有很大需求的。目前銷售的還是通用新冠試劑盒,公司已經開發了能鑑別變異株的產品,國際上變異病毒檢測試劑盒已有訂單需求,公司也會時刻關注病毒的變異情況,及時開發出有價值的產品。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.